APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD14 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CD14 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchCD14 Antibody Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal CD14 Antibody Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal CD14 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD14 Antibody Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal CD14 Antibody Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global CD14 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CD14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CD14 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CD14 Antibody market include Thermo Fisher Scientific, Merck, Boster Biological Technology, Santa Cruz Biotechnology, NSJ Bioreagents, Miltenyi Biotec, Leinco Technologies, FineTest and EXBIO, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CD14 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD14 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD14 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CD14 Antibody market.

CD14 Antibody Segment by Company

Thermo Fisher Scientific

Merck

Boster Biological Technology

Santa Cruz Biotechnology

NSJ Bioreagents

Miltenyi Biotec

Leinco Technologies

FineTest

EXBIO

Everest Biotech

Bio-Rad

BioLegend

Beckman Coulter

Atlas Antibodies

CD14 Antibody Segment by Type

Polyclonal

Monoclonal

CD14 Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Flow Cytometry

Others

CD14 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CD14 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CD14 Antibody key companies, revenue, market share, and recent developments.

3. To split the CD14 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CD14 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CD14 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze CD14 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD14 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD14 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD14 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD14 Antibody industry.

Chapter 3: Detailed analysis of CD14 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CD14 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CD14 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CD14 Antibody Industry Trends Table 2. CD14 Antibody Industry Drivers Table 3. CD14 Antibody Industry Opportunities and Challenges Table 4. CD14 Antibody Industry Restraints Table 5. Global CD14 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CD14 Antibody Revenue Share by Company (2021-2026) Table 7. Global CD14 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CD14 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global CD14 Antibody Company, Product Type & Application Table 10. Global CD14 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CD14 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global CD14 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CD14 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CD14 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CD14 Antibody Sales Value Share by Type (2021-2026) Table 20. Global CD14 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Paraffin Table 22. Significant Companies of Immunohistochemistry Frozen Table 23. Significant Companies of Flow Cytometry Table 24. Significant Companies of Others Table 25. Global CD14 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global CD14 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global CD14 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global CD14 Antibody Sales Value Share by Application (2021-2026) Table 29. Global CD14 Antibody Sales Value Share by Application (2027-2032) Table 30. Global CD14 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global CD14 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global CD14 Antibody Sales Value Share by Region (2021-2026) Table 33. Global CD14 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global CD14 Antibody Sales Value Share by Region (2027-2032) Table 35. Global CD14 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global CD14 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global CD14 Antibody Sales Value Market Share by Country (2021-2026) Table 38. Global CD14 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global CD14 Antibody Sales Value Market Share by Country (2027-2032) Table 40. Thermo Fisher Scientific Company Information Table 41. Thermo Fisher Scientific Business Overview Table 42. Thermo Fisher Scientific CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Thermo Fisher Scientific CD14 Antibody Product Portfolio Table 44. Thermo Fisher Scientific Recent Development Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck CD14 Antibody Product Portfolio Table 49. Merck Recent Development Table 50. Boster Biological Technology Company Information Table 51. Boster Biological Technology Business Overview Table 52. Boster Biological Technology CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Boster Biological Technology CD14 Antibody Product Portfolio Table 54. Boster Biological Technology Recent Development Table 55. Santa Cruz Biotechnology Company Information Table 56. Santa Cruz Biotechnology Business Overview Table 57. Santa Cruz Biotechnology CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Santa Cruz Biotechnology CD14 Antibody Product Portfolio Table 59. Santa Cruz Biotechnology Recent Development Table 60. NSJ Bioreagents Company Information Table 61. NSJ Bioreagents Business Overview Table 62. NSJ Bioreagents CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. NSJ Bioreagents CD14 Antibody Product Portfolio Table 64. NSJ Bioreagents Recent Development Table 65. Miltenyi Biotec Company Information Table 66. Miltenyi Biotec Business Overview Table 67. Miltenyi Biotec CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Miltenyi Biotec CD14 Antibody Product Portfolio Table 69. Miltenyi Biotec Recent Development Table 70. Leinco Technologies Company Information Table 71. Leinco Technologies Business Overview Table 72. Leinco Technologies CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Leinco Technologies CD14 Antibody Product Portfolio Table 74. Leinco Technologies Recent Development Table 75. FineTest Company Information Table 76. FineTest Business Overview Table 77. FineTest CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. FineTest CD14 Antibody Product Portfolio Table 79. FineTest Recent Development Table 80. EXBIO Company Information Table 81. EXBIO Business Overview Table 82. EXBIO CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. EXBIO CD14 Antibody Product Portfolio Table 84. EXBIO Recent Development Table 85. Everest Biotech Company Information Table 86. Everest Biotech Business Overview Table 87. Everest Biotech CD14 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Everest Biotech CD14 Antibody Product Portfolio Table 89. Everest Biotech Recent Development Table 90. Bio-Rad Company Information Table 91. Bio-Rad Business Overview Table 92. Bio-Rad CD14 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bio-Rad CD14 Antibody Product Portfolio Table 94. Bio-Rad Recent Development Table 95. BioLegend Company Information Table 96. BioLegend Business Overview Table 97. BioLegend CD14 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. BioLegend CD14 Antibody Product Portfolio Table 99. BioLegend Recent Development Table 100. Beckman Coulter Company Information Table 101. Beckman Coulter Business Overview Table 102. Beckman Coulter CD14 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Beckman Coulter CD14 Antibody Product Portfolio Table 104. Beckman Coulter Recent Development Table 105. Atlas Antibodies Company Information Table 106. Atlas Antibodies Business Overview Table 107. Atlas Antibodies CD14 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Atlas Antibodies CD14 Antibody Product Portfolio Table 109. Atlas Antibodies Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. CD14 Antibody Product Image Figure 2. Global CD14 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD14 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global CD14 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global CD14 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CD14 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CD14 Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Paraffin Image Figure 13. Immunohistochemistry Frozen Image Figure 14. Flow Cytometry Image Figure 15. Others Image Figure 16. Global CD14 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global CD14 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global CD14 Antibody Sales Value Share by Application (2021-2032) Figure 19. Global CD14 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global CD14 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America CD14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 22. North America CD14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe CD14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. Europe CD14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific CD14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific CD14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America CD14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. South America CD14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa CD14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa CD14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt CD14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt CD14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt CD14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Flow Cytometry
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • Boster Biological Technology
  • Santa Cruz Biotechnology
  • NSJ Bioreagents
  • Miltenyi Biotec
  • Leinco Technologies
  • FineTest
  • EXBIO
  • Everest Biotech
  • Bio-Rad
  • BioLegend
  • Beckman Coulter
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD14 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD14 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CD14 Antibody Market Dynamics
  1. 2.1 CD14 Antibody Industry Trends
  2. 2.2 CD14 Antibody Industry Drivers
  3. 2.3 CD14 Antibody Industry Opportunities and Challenges
  4. 2.4 CD14 Antibody Industry Restraints
3 CD14 Antibody Market by Company
  1. 3.1 Global CD14 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global CD14 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global CD14 Antibody Company Ranking (2024-2026)
  4. 3.4 Global CD14 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global CD14 Antibody Company Product Type and Application
  6. 3.6 Global CD14 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CD14 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CD14 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CD14 Antibody Market by Type
  1. 4.1 CD14 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global CD14 Antibody Sales Value by Type
  5. 4.2.1 Global CD14 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CD14 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global CD14 Antibody Sales Value Share by Type (2021-2032)
5 CD14 Antibody Market by Application
  1. 5.1 CD14 Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Paraffin
  3. 5.1.2 Immunohistochemistry Frozen
  4. 5.1.3 Flow Cytometry
  5. 5.1.4 Others
  6. 5.2 Global CD14 Antibody Sales Value by Application
  7. 5.2.1 Global CD14 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global CD14 Antibody Sales Value by Application (2021-2032)
  9. 5.2.3 Global CD14 Antibody Sales Value Share by Application (2021-2032)
6 CD14 Antibody Regional Value Analysis
  1. 6.1 Global CD14 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD14 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global CD14 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global CD14 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD14 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America CD14 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CD14 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe CD14 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CD14 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CD14 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CD14 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America CD14 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CD14 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CD14 Antibody Sales Value Share by Country, 2025 VS 2032
7 CD14 Antibody Country-level Value Analysis
  1. 7.1 Global CD14 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CD14 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global CD14 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global CD14 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CD14 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CD14 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CD14 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CD14 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CD14 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CD14 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CD14 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CD14 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CD14 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CD14 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CD14 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CD14 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CD14 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CD14 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CD14 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CD14 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CD14 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CD14 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CD14 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CD14 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CD14 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CD14 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CD14 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CD14 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CD14 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CD14 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CD14 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CD14 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CD14 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CD14 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CD14 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific CD14 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific CD14 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck CD14 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck CD14 Antibody Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Boster Biological Technology
  14. 8.3.1 Boster Biological Technology Company Information
  15. 8.3.2 Boster Biological Technology Business Overview
  16. 8.3.3 Boster Biological Technology CD14 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boster Biological Technology CD14 Antibody Product Portfolio
  18. 8.3.5 Boster Biological Technology Recent Developments
  19. 8.4 Santa Cruz Biotechnology
  20. 8.4.1 Santa Cruz Biotechnology Company Information
  21. 8.4.2 Santa Cruz Biotechnology Business Overview
  22. 8.4.3 Santa Cruz Biotechnology CD14 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santa Cruz Biotechnology CD14 Antibody Product Portfolio
  24. 8.4.5 Santa Cruz Biotechnology Recent Developments
  25. 8.5 NSJ Bioreagents
  26. 8.5.1 NSJ Bioreagents Company Information
  27. 8.5.2 NSJ Bioreagents Business Overview
  28. 8.5.3 NSJ Bioreagents CD14 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 NSJ Bioreagents CD14 Antibody Product Portfolio
  30. 8.5.5 NSJ Bioreagents Recent Developments
  31. 8.6 Miltenyi Biotec
  32. 8.6.1 Miltenyi Biotec Company Information
  33. 8.6.2 Miltenyi Biotec Business Overview
  34. 8.6.3 Miltenyi Biotec CD14 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Miltenyi Biotec CD14 Antibody Product Portfolio
  36. 8.6.5 Miltenyi Biotec Recent Developments
  37. 8.7 Leinco Technologies
  38. 8.7.1 Leinco Technologies Company Information
  39. 8.7.2 Leinco Technologies Business Overview
  40. 8.7.3 Leinco Technologies CD14 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Leinco Technologies CD14 Antibody Product Portfolio
  42. 8.7.5 Leinco Technologies Recent Developments
  43. 8.8 FineTest
  44. 8.8.1 FineTest Company Information
  45. 8.8.2 FineTest Business Overview
  46. 8.8.3 FineTest CD14 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 FineTest CD14 Antibody Product Portfolio
  48. 8.8.5 FineTest Recent Developments
  49. 8.9 EXBIO
  50. 8.9.1 EXBIO Company Information
  51. 8.9.2 EXBIO Business Overview
  52. 8.9.3 EXBIO CD14 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 EXBIO CD14 Antibody Product Portfolio
  54. 8.9.5 EXBIO Recent Developments
  55. 8.10 Everest Biotech
  56. 8.10.1 Everest Biotech Company Information
  57. 8.10.2 Everest Biotech Business Overview
  58. 8.10.3 Everest Biotech CD14 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Everest Biotech CD14 Antibody Product Portfolio
  60. 8.10.5 Everest Biotech Recent Developments
  61. 8.11 Bio-Rad
  62. 8.11.1 Bio-Rad Company Information
  63. 8.11.2 Bio-Rad Business Overview
  64. 8.11.3 Bio-Rad CD14 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bio-Rad CD14 Antibody Product Portfolio
  66. 8.11.5 Bio-Rad Recent Developments
  67. 8.12 BioLegend
  68. 8.12.1 BioLegend Company Information
  69. 8.12.2 BioLegend Business Overview
  70. 8.12.3 BioLegend CD14 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioLegend CD14 Antibody Product Portfolio
  72. 8.12.5 BioLegend Recent Developments
  73. 8.13 Beckman Coulter
  74. 8.13.1 Beckman Coulter Company Information
  75. 8.13.2 Beckman Coulter Business Overview
  76. 8.13.3 Beckman Coulter CD14 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Beckman Coulter CD14 Antibody Product Portfolio
  78. 8.13.5 Beckman Coulter Recent Developments
  79. 8.14 Atlas Antibodies
  80. 8.14.1 Atlas Antibodies Company Information
  81. 8.14.2 Atlas Antibodies Business Overview
  82. 8.14.3 Atlas Antibodies CD14 Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Atlas Antibodies CD14 Antibody Product Portfolio
  84. 8.14.5 Atlas Antibodies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst